As of 2025-07-09, the Fair Value of NovaBay Pharmaceuticals Inc (NBY) is -6.21 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.66 USD, the upside of NovaBay Pharmaceuticals Inc is -1,036.80%.
With the market price of 0.66 USD and our fair value calculation, NovaBay Pharmaceuticals Inc (NBY) is not a good investment. Investing in NBY stocks now will result in a potential loss of 1,036.80%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -11.04 | -5.82 | -10.61 | -9.64 | -7.22 | -8.87 |
| YoY growth | -14.29% | 47.28% | -82.30% | 9.14% | 25.07% | -3.02% |
| Market Cap (mil) | 3.86 |
| P/E | |
| Forward P/E |
| EPS | -1.24 |
| Avg earnings growth rate | -3.02% |
| TTM earnings | -7.22 |